Startups
Crystalys Therapeutics
Develops therapies for gout, focusing on patients whose uric acid levels and symptoms are inadequately controlled by current treatments. Its lead investigational medicine, dotinurad, is an oral selective URAT1 inhibitor intended to reduce uric acid reabsorption in the kidneys. The company is conducting Phase 3 registration trials and a Phase 2 study for difficult-to-treat gout.
Team
Ashwin RamCo-Founder and Chief Operating Officer |
Chris GarabedianBoard Member |
David JinBoard Member |
DeAnne ReidCo-Founder and Chief Administrative Officer |
James MackayCo-Founder, President, CEO and Board Member |
 Kenneth HarrisonBoard Member |
Nihar BhaktaCo-Founder and Chief Medical Officer |
Rajeev DadooBoard Member |
 Seth H.Z. FischerBoard Member |
 Tim WalbertIndependent Board Chair |